581-45-3

Basic information

• Product Name: 1,2,3,4,5,6-HEXAHYDRO-[4,4']BIPYRIDINYL
• Synonyms: 4-(4-PYRIDINYL)PIPERIDINE;4-PYRIDIN-4-YL-PIPERIDINE;4-PIPERIDINE-4-YL-PYRIDINE;4-PIPERIDIN-4-YLPYRIDINE;1,2,3,4,5,6-HEXAHYDRO-[4,4']BIPYRIDINYL;TIMTEC-BB SBB010178;4-PYRIDIN-4-YL-PIPERIDINE >98%;4-(4-Piperidinyl)pyridine
• CAS NO: 581-45-3
• Molecular Formula: C₁₀H₁₄N₂
• Molecular Weight: 162.23
• Mol File: 581-45-3.mol
• Article Data: 10

Chemical Properties

• Melting Point: 84.0 to 88.0 °C
• Boiling Point: 86-88°C
• Flash Point: 120.4 °C
• Appearance: /
• Density: 1.0534 (rough estimate)
• Vapor Pressure: 0.00188mmHg at 25°C
• Refractive Index: 1.5430 (estimate)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 9.92±0.10(Predicted)
• CAS DataBase Reference: 1,2,3,4,5,6-HEXAHYDRO-[4,4']BIPYRIDINYL(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,3,4,5,6-HEXAHYDRO-[4,4']BIPYRIDINYL(581-45-3)
• EPA Substance Registry System: 1,2,3,4,5,6-HEXAHYDRO-[4,4']BIPYRIDINYL(581-45-3)

Safety Data

• Hazard Codes: T,Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 581-45-3(Hazardous Substances Data)

Usage

General Description

1,2,3,4,5,6-HEXAHYDRO-[4,4']BIPYRIDINYL is a chemical compound with a molecular structure that consists of two linked pyridine rings, forming a six-membered ring system. It is a colorless liquid that is used in various industrial processes, including the production of pharmaceuticals, agrochemicals, and organic synthesis. 1,2,3,4,5,6-HEXAHYDRO-[4,4']BIPYRIDINYL is also known for its potential use in the development of new materials and technologies. It has been studied for its ability to act as a ligand in coordination chemistry and its potential use in catalytic applications. 1,2,3,4,5,6-HEXAHYDRO-[4,4']BIPYRIDINYL is also a key intermediate in the synthesis of various other chemical compounds, making it a valuable building block in the chemical industry.

InChI:InChI=1/C10H14N2/c1-5-11-6-2-9(1)10-3-7-12-8-4-10/h1-2,5-6,10,12H,3-4,7-8H2

Upstream product

• 550371-76-1 Boc-4-pyridin-4-yl-piperidine 
• 39182-30-4 4,4'-bipyridine N-monoxide 
• 553-26-4 4,4'-bipyridine 

Downstream Products

• 1026063-27-3 1-(4-isocyanato-phenyl)-1,2,3,4,5,6-hexahydro-[4,4']bipyridinyl 
• 666851-65-6 2-[1,1-dimethyl-2-oxo-2-azabicyclo[2.2.1]heptan-7-ylethyl]-4-[2-(4-pyrid-4-ylpiperidin-1-yl)ethyl]-5-(3,5-dimethylphenyl)-6H-thieno[2,3-b]pyrrole 
• 667940-58-1 2-(1,1-dimethyl-2-oxo-2-(7-azabicyclo[2.2.1]heptan-7-yl)ethyl)-4-[(1S)-1-methyl-2-(4-{pyridin-4-yl}piperidin-1-yl)carbonylamino-ethyl]-5-(3,5-dimethylphenyl)-6H-thieno[2,3-b]pyrrole 
• 666852-62-6 2-(1,1-dimethyl-2-oxo-2-pyrrolidin-1-ylethyl)-5-(3,5-dimethylphenyl)-4-[(4-pyridin-4-ylpiperidin-1-yl)methyl]-6H-thieno[2,3-b]pyrrole 
• 550371-76-1 Boc-4-pyridin-4-yl-piperidine 
• 1227046-96-9 C₂₇H₃₃N₇ 

Relevant articles and documents

DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS

The present invention relates to new drug combinations which contain in addition to one or more PDE4-inhibitors at least one NSAID (=non-steroidal anti-inflammatory drug) (2), processes for preparing them and their use in treating in particular respiratory complaints such as for example COPD, chronic sinusitis and asthma. The invention particularly relates to those drug combinations which contain, in addition to one or more, preferably one PDE4 inhibitor of general formula 1 wherein X is SO or SO2, but preferably SO, and wherein R1, R2, R3 and R4 have the meanings given in claim 1, at least one NSAID (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.

1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle

It is intended to provide a drug which is efficacious against pathological conditions relating to arginine-vasopressin V1b receptor. More particularly speaking, it is intended to provide a drug which has a therapeutic or preventive effect on depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, hypertension, digestive diseases, drug addiction, epilepsy, brain infarction, brain ischemia, brain edema, head injury, inflammation, immune diseases, alopecia and so on. As the results of intensive studies, a novel 1,3-dihydro-2H-indol-2-one compound and a pyrrolidin-2-one compound fused with a heteroaromatic ring, which are highly selective antagonists of arginine-vasopressin V1b receptor, have high metabolic stabilities and show favorable brain penetration and high plasma concentrations, are found, thereby achieving the above objective.

Heterocyclic compounds useful as oxido-squalene cyclase inhibitors

This invention concerns heterocyclic derivatives of formula (I) which are useful in inhibiting oxido-squalene cyclase, processes for their preparation and pharmaceutical compositions containing them. The present invention is also concerned with heterocyclic derivatives capable of inhibiting cholesterol biosynthesis and hence in lowering cholesterol levels in blood plasma. The present invention also relates to methods of using such heterocyclic derivatives in diseases and medical conditions such as hypercholesterolemia and atherosclerosis.